LONDON (Reuters) Jun 14 – A British biotech firm said on Friday that early tests of an anti-smoking vaccine showed it was safe and that it effectively produced antibodies against nicotine.
Xenova Plc said the first ever clinical trial of the anti-smoking vaccine showed that its product, TA-NIC, generated antibodies that bind to nicotine. The firm, which is also developing a vaccine against cocaine, believes that if it can stop nicotine from reaching the brain, it can solve smokers’ addiction
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!